Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease

Tools
- Tools
+ Tools

Cooper, K., Davies, Robin P., Raftery, James, Professor and Roderick, Paul (2008) Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease. Journal of the Operational Research Society, Vol.59 (No.9). pp. 1173-1181. doi:10.1057/palgrave.jors.2602468 ISSN 0160-5682.

Research output not available from this repository.

Request-a-Copy directly from author or use local Library Get it For Me service.

Official URL: http://dx.doi.org/10.1057/palgrave.jors.2602468

Request Changes to record.

Abstract

A discrete event simulation model of the patient pathways in the treatment of coronary heart disease (CHD) was used to quantify the health gains and costs associated with increasing secondary prevention drugs prescription for patients with CHD based on the level recommended in the National Service Framework for the UK. A Gompertz distribution was sampled for time to failure ( death or non-fatal heart attack). The time to failure was modified in relation to the reduced risk of failure for those on the relevant drugs. The results from the model were validated against national data. Increasing the levels of prescription of secondary prevention drugs to those patients with CHD might prevent 100 deaths per million population per year and cost an additional 4 pound million per million population per year. With cost per life year saved of 5520 pound, this appears good value for money compared with other health technologies.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Coronary heart disease -- Mathematical models, Coronary heart disease -- Treatment -- Cost effectiveness, Coronary heart disease -- Prevention
Journal or Publication Title: Journal of the Operational Research Society
Publisher: Palgrave Macmillan Ltd.
ISSN: 0160-5682
Official Date: September 2008
Dates:
DateEvent
September 2008Published
Volume: Vol.59
Number: No.9
Number of Pages: 9
Page Range: pp. 1173-1181
DOI: 10.1057/palgrave.jors.2602468
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: National Centre for Health Outcomes Development

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us